126 related articles for article (PubMed ID: 23446656)
1. Study on the potential benefit of adding topical bromfenac to intravitreal injections of ranibizumab for the therapy of exudative age-related macular degeneration.
Jonas JB; Libondi T
Retina; 2013 May; 33(5):1093. PubMed ID: 23446656
[No Abstract] [Full Text] [Related]
2. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.
Gomi F; Sawa M; Tsujikawa M; Nishida K
Retina; 2012 Oct; 32(9):1804-10. PubMed ID: 22718152
[TBL] [Abstract][Full Text] [Related]
3. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration.
Zweifel SA; Engelbert M; Khan S; Freund KB
Retina; 2009; 29(10):1527-31. PubMed ID: 19898185
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study.
Flaxel C; Schain MB; Hamon SC; Francis PJ
Retina; 2012 Mar; 32(3):417-23. PubMed ID: 21862953
[TBL] [Abstract][Full Text] [Related]
5. Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion.
Shimura M; Yasuda K
Br J Ophthalmol; 2015 Feb; 99(2):215-9. PubMed ID: 25185254
[TBL] [Abstract][Full Text] [Related]
6. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
Park SS; Daftari I; Phillips T; Morse LS
Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal ranibizumab for treatment of fibrovascular pigment epithelial detachment in age-related macular degeneration.
Yolcu U; Tas A; Altun S
Can J Ophthalmol; 2015 Oct; 50(5):395. PubMed ID: 26455979
[No Abstract] [Full Text] [Related]
8. A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration.
Russo A; Costagliola C; Delcassi L; Romano MR; Semeraro F
Br J Ophthalmol; 2013 Oct; 97(10):1273-6. PubMed ID: 23873901
[TBL] [Abstract][Full Text] [Related]
9. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
10. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
[TBL] [Abstract][Full Text] [Related]
11. Treatment of wet age-related macular degeneration by ranibizumab in "real life" in France: treatment behaviours and associated visual outcome.
Souied EH; Cohen SY; de Pouvourville G; Dupeyron G; Latour E; Ponthieux A; Weber M
Acta Ophthalmol; 2015 Mar; 93(2):e179-80. PubMed ID: 25377519
[No Abstract] [Full Text] [Related]
12. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
[TBL] [Abstract][Full Text] [Related]
13. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
[TBL] [Abstract][Full Text] [Related]
14. Ultrasound assessment of ocular vascular effects of repeated intravitreal injections of ranibizumab for wet age-related macular degeneration.
Bonnin P; Pournaras JA; Makowiecka K; Krivosic V; Kedra AW; Le Gargasson JF; Gaudric A; Levy BI; Cohen YS; Tadayoni R; Massin P
Acta Ophthalmol; 2014 Aug; 92(5):e382-7. PubMed ID: 25043792
[TBL] [Abstract][Full Text] [Related]
15. LuceDex: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration.
Ranchod TM; Ray SK; Daniels SA; Leong CJ; Ting TD; Verne AZ
Retina; 2013 Sep; 33(8):1600-4. PubMed ID: 23549100
[TBL] [Abstract][Full Text] [Related]
16. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
Torjesen I
BMJ; 2013 Jul; 347():f4678. PubMed ID: 23881948
[No Abstract] [Full Text] [Related]
17. Multifocal pupillography identifies ranibizumab-induced changes in retinal function for exudative age-related macular degeneration.
Sabeti F; Maddess T; Essex RW; James AC
Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):253-60. PubMed ID: 22159011
[TBL] [Abstract][Full Text] [Related]
18. Combination of bevacizumab and bromfenac therapy in age-related macular degeneration: a pilot study.
Wyględowska-Promieńska D; Piotrowska-Gwóźdź A; Piotrowska-Seweryn A; Mazur-Piotrowska G; Rokicki W
Med Sci Monit; 2014 Jul; 20():1168-75. PubMed ID: 25006692
[TBL] [Abstract][Full Text] [Related]
19. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
20. [Vitreomacular traction in patients with exudative age-related macular degeneration].
Abreu González R; Gallego-Pinazo R; Pérez Muñoz D; Pascual-Camps CI; Pérez Méndez L
Arch Soc Esp Oftalmol; 2014 Jun; 89(6):255. PubMed ID: 24332686
[No Abstract] [Full Text] [Related]
[Next] [New Search]
